X51ef25f8.0e4b.4c31.bd54.aee0c5fc11d9
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 84
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.490
- TGF_BETA_SIGNALING+0.420
- PROTEIN_SECRETION+0.370
- MITOTIC_SPINDLE+0.320
- INTERFERON_GAMMA_RESPONSE+0.290
- NOTCH_SIGNALING+0.240
- COMPLEMENT+0.190
- UV_RESPONSE_DN+0.160
- DNA_REPAIR+0.140
- G2M_CHECKPOINT+0.140
Top 10 suppressed
- MYC_TARGETS_V2-0.460
- UV_RESPONSE_UP-0.290
- MYOGENESIS-0.270
- UNFOLDED_PROTEIN_RESPONSE-0.230
- ANGIOGENESIS-0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
- KRAS_SIGNALING_DN-0.180
- SPERMATOGENESIS-0.180
- TNFA_SIGNALING_VIA_NFKB-0.170
- E2F_TARGETS-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4296102 | — | cohortA1 | 0.742 |
| 2 | TCGA-E9-A24A-01A-11R-A169-07 | — | B | 0.646 |
| 3 | SRR934738 | — | — | 0.643 |
| 4 | 25d48b78-8622-42af-b33f-4034a42f30cb | — | — | 0.638 |
| 5 | SRR1797292 | — | cohortSC | 0.624 |
| 6 | TCGA-69-7761-01A-11R-2170-07 | — | cohortA1 | 0.620 |
| 7 | SJEPD030584_D1.RNA-Seq | EPN | Supratentorial EPN | 0.619 |
| 8 | DRR168512 | — | — | 0.614 |
| 9 | TCGA-FD-A3SR-01A-11R-A22U-07 | — | — | 0.613 |
| 10 | TCGA-AN-A0XP-01A-11R-A109-07 | — | B | 0.612 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.140 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.070 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.030 | Inavolisib | — uncovered |